Portal de Periódicos da CAPES

Predictors of Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Results From the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care Project

2008; Lippincott Williams & Wilkins; Volume: 180; Issue: 2 Linguagem: Inglês

10.1016/j.juro.2008.04.016

1527-3792

George J. Huang, Ann S. Hamilton, Mary Lo, John P. Stein, David F. Penson,

Colorectal Cancer Screening and Detection

No AccessJournal of UrologyAdult Urology1 Aug 2008Predictors of Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Results From the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care Project George J. Huang, Ann S. Hamilton, Mary Lo, John P. Stein, and David F. Penson George J. HuangGeorge J. Huang Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California , Ann S. HamiltonAnn S. Hamilton Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California , Mary LoMary Lo Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California , John P. SteinJohn P. Stein Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California , and David F. PensonDavid F. Penson Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California View All Author Informationhttps://doi.org/10.1016/j.juro.2008.04.016AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In response to variations in cancer care organizations have developed clinical guidelines. In the case of nonmuscle invasive bladder cancer, also known as superficial bladder cancer, 2 similar sets of guidelines were released in the late 1990s that provide care recommendations. We examined patterns of intravesical therapy use in nonmuscle invasive bladder cancer in 2003 to determine whether disparities remained in the quality of cancer care. Materials and Methods: Data from the SEER (Surveillance, Epidemiology and End Results) Program 2003 Bladder Cancer Patterns of Care project were used. Subjects newly diagnosed with nonmuscle invasive bladder cancer in 2003 were included. Clinical and sociodemographic data were obtained from the SEER Program and a detailed medical record review. Statistical analysis was performed to identify independent predictors of intravesical therapy in the entire cohort and in a subset of patients at high risk. Results: A total of 685 patients were included in the study, of whom 216 (31.5%) received intravesical therapy. In addition to higher tumor stage and grade, intravesical therapy was independently associated with race/ethnicity and geographic region. Of the subset of 350 patients at high risk 42% received intravesical therapy. Stage, grade, race/ethnicity and geographic region were independently associated with intravesical therapy in this subcohort. Conclusions: These data suggest the underuse of intravesical therapy even in patients with high risk nonmuscle invasive bladder cancer as well as disparities in the quality of care. Barriers to using this cancer treatment must be identified, particularly in individuals at higher risk, and providers must become more aware of existing clinical guidelines. References 1 : Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst2005; 97: 12110. Google Scholar 2 : Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst2002; 94: 490. Google Scholar 3 : Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol2005; 23: 7881. Google Scholar 4 : Variations in prostate cancer patterns of care: is it the quality of care or the quality of the data?. J Clin Oncol2005; 23: 7783. Google Scholar 5 : Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst2001; 93: 501. Google Scholar 6 : Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS): The American Urological Association. J Urol1999; 162: 1697. Link, Google Scholar 7 : NCCN urothelial cancer practice guidelines: National Comprehensive Cancer Network. Oncology (Williston Park)1998; 12: 225. Google Scholar 8 : Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol2007; 178: 2314. Link, Google Scholar 9 : Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol2000; 164: 680. Link, Google Scholar 10 : Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors: 1976. J Urol1976; 116: 180. Abstract, Google Scholar 11 : Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am2005; 32: 121. Google Scholar 12 : Bladder carcinoma in situ in 2003: state of the art. Eur Urol2004; 45: 142. Google Scholar 13 : Bladder and upper tract urothelial cancer. J Urol2007; 177: 1636. Link, Google Scholar 14 : Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst2001; 93: 1864. Google Scholar 15 : Social and economic factors in the choice of lung cancer treatment: A population-based study in two rural states. N Engl J Med1988; 318: 612. Google Scholar 16 : Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the Surveillance, Epidemiology, and End Results Program. J Urol2005; 173: 2085. Link, Google Scholar 17 : Racial differences in the treatment of early-stage lung cancer. N Engl J Med1999; 341: 1198. Google Scholar 18 : Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol2002; 20: 1192. Google Scholar 19 : Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol2003; 170: 1765. Link, Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetailsCited ByMossanen M, Ingham M, Leow J, Tinay I, Wang Y, Krasnow R, Preston M, Bellmunt J, Chung B, Rosenberg J and Chang S (2018) Exploring Patterns of Mitomycin C Use in Community Practice UrologyUrology Practice, VOL. 5, NO. 1, (7-14), Online publication date: 1-Jan-2018.Cookson M, Chang S, Oefelein M, Gallagher J, Schwartz B and Heap K (2018) National Practice Patterns for Immediate Postoperative Instillation of Chemotherapy in Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 187, NO. 5, (1571-1576), Online publication date: 1-May-2012.Lee C, Barocas D, Globe D, Oefelein M, Colayco D, Bruno A, O'Day K and Bramley T (2018) Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer CasesJournal of Urology, VOL. 188, NO. 6, (2114-2119), Online publication date: 1-Dec-2012.Lu Z, Yeh T, Wang J, Chen L, Lyness G, Xin Y, Wientjes M, Bergdall V, Couto G, Alvarez-Berger F, Kosarek C and Au J (2018) Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer TherapyJournal of Urology, VOL. 185, NO. 4, (1478-1483), Online publication date: 1-Apr-2011. Volume 180Issue 2August 2008Page: 520-524 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordsstandardsquality of health carecarcinoma, transitional cellSEER ProgrambladderMetricsAuthor Information George J. Huang Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California More articles by this author Ann S. Hamilton Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California More articles by this author Mary Lo Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California More articles by this author John P. Stein Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California More articles by this author David F. Penson Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California More articles by this author Expand All Advertisement PDF DownloadLoading ...